Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

Inclusion Criteria: * Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local standard of care and product label for the first time. * Patients must be willing and able to use an electronic device to complete the study patient-reported outcome (PRO). Exclusion Criteria: \- Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.